Business
Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESM...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY and SAN DIEGO, Sept. 11, 2017\n\n\n\nAdditional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients\n\nLargest immuno-oncolytic virus safety database reported to-date demonstrates REOLYSIN® is safe and well-tolerated\n\n\n\nCALGARY and SAN DIEGO, Sept. 11, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, a first-in-class, systemically delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that two poster presentations focused on REOLYSIN were presented on Sunday, September 10 at the European Society for Medical Oncology (ESMO) 2017 Congress.  \n\n\n1193P, Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients, Dr. Andres Gutierrez, Oncolytics Biotech\n\n\"Our poster on pooled data outlines the largest safety database available to date for an oncolytic virus and demonstrates that REOLYSIN is safe and well tolerated when administered in combination with chemotherapy,\" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. \"Regarding the metastatic breast cancer data presented within this pooled safety data, further analysis of our phase two study highlights a doubling of overall survival benefit for patients with hormone receptor double-positive, HER2-negative breast cancer – a major genetic subgroup – when treated with REOLYSIN/paclitaxel combination treatment versus paclitaxel alone. The poster demonstrates a strong safety profile and statistically significant efficacy as we continue to advance towards regulatory approval for REOLYSIN in this indication.\"\n\nIn the IND 213 randomized phase 2 study in metas...